Greg McKee, Chairman and CEO, Tryp Therapeutics Inc.
Greg McKee is Chairman and CEO of Tryp Therapeutics, an early stage drug development company focused on bringing compounds to market with known activity and safety profiles for the treatment of rare diseases with unmet medical needs. Greg was a co-founder and managing director of Torrent Ventures, a California focused digital health and medical technology firm that supports promising companies pursing break through solutions in drug development, genomics, diagnostics, medical devices, drug delivery and digital health technologies.
Previously Mr. McKee was chief executive officer of CONNECT, a start-up accelerator focused on creating and scaling great innovative companies across the life science and technology disciplines. Prior to CONNECT he was chairman, president and chief executive officer of publicly traded Nventa Biopharmacueticals which merged with Akela Pharma. Additionally, he held senior management roles at Valentis, Inc., and Genzyme Corporation, which was acquired by Sanofi for $22 billion. Mr. McKee has lived and worked in Tokyo, Japan, for seven years in investment management (Mizuho Group) during which time he managed $550M in the Japanese equity market, and investment banking (UBS). He also held an appointment as senior advisor to the Former Minister of Foreign Affairs of Japan and speaks fluent Japanese. Mr. McKee has also lived and worked in Singapore for 2 years managing Genzyme’s business units in South East Asia and mainland China.
Mr. McKee earned a B.A. in Economics from the University of Washington, a M.A. in International Studies from The Joseph H. Lauder Institute and an M.B.A from the Wharton School, at the University of Pennsylvania. He has been a member of YPO since 2006, Chapter Chair YPO Coastal San Diego, and on the Leadership team of the YPO Deal Network and Personal Investing Network. He is a classically trained violist and pianist and is an avid ocean swimmer, alpine skier and mountaineer.